Literature DB >> 20463350

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

Richard A Feelders, Christiaan de Bruin, Alberto M Pereira, Johannes A Romijn, Romana T Netea-Maier, Ad R Hermus, Pierre M Zelissen, Ramona van Heerebeek, Frank H de Jong, Aart-Jan van der Lely, Wouter W de Herder, Leo J Hofland, Steven W Lamberts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20463350     DOI： 10.1056/NEJMc1000094

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  69 in total

Review 1.  Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly.

Authors:  M G Baroni; F Giorgino; V Pezzino; C Scaroni; A Avogaro
Journal:  J Endocrinol Invest       Date:  2015-12-30       Impact factor: 4.256

2.  Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.

Authors:  Eleni Daniel; Simon Aylwin; Omar Mustafa; Steve Ball; Atif Munir; Kristien Boelaert; Vasileios Chortis; Daniel J Cuthbertson; Christina Daousi; Surya P Rajeev; Julian Davis; Kelly Cheer; William Drake; Kirun Gunganah; Ashley Grossman; Mark Gurnell; Andrew S Powlson; Niki Karavitaki; Isabel Huguet; Tara Kearney; Kumar Mohit; Karim Meeran; Neil Hill; Aled Rees; Andrew J Lansdown; Peter J Trainer; Anna-Elisabeth H Minder; John Newell-Price
Journal:  J Clin Endocrinol Metab       Date:  2015-09-09       Impact factor: 5.958

Review 3.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

4.  Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.

Authors:  S Cannavo; E Messina; A Albani; F Ferrau; V Barresi; S Priola; F Esposito; F Angileri
Journal:  Endocrine       Date:  2015-04-16       Impact factor: 3.633

5.  Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

Authors:  Troy H Dillard; S Humayun Gultekin; Johnny B Delashaw; Chris G Yedinak; Edward A Neuwelt; Maria Fleseriu
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 6.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 7.  Update in the medical therapy of Cushing's disease.

Authors:  Lynnette K Nieman
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-08       Impact factor: 3.243

8.  Medical combination therapies in Cushing's disease.

Authors:  Lucio Vilar; Luciana A Naves; Márcio C Machado; Marcello D Bronstein
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

9.  Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.

Authors:  Jessica MacKenzie Feder; Isabelle Bourdeau; Sophie Vallette; Hugues Beauregard; Louis-Georges Ste-Marie; André Lacroix
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

10.  Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.

Authors:  R van der Pas; C de Bruin; A M Pereira; J A Romijn; R T Netea-Maier; A R Hermus; P M Zelissen; F H de Jong; A J van der Lely; W W de Herder; S M Webb; S W J Lamberts; L J Hofland; R A Feelders
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.